Director: C. Kent Osborne M.D. has committed 50% of his effort to serve as Cancer Center Director. AsDirector his responsibilities include:1. Oversee cancer-related clinical and research activities at BCMCC.2. Promote interdisciplinary coordination and collaboration.3. Facilitate interactions and collaborations with other medical institutions and cancer centers.4. Organize and oversee the Shared Resources of the Cancer Center, create new Shared Resources, oreliminate obsolete Resources as necessary to best carry out the Cancer Center's mission and goals.5. Develop and manage the Cancer Center's budget and its philanthropic gifts.6. Recruit new faculty in cooperation with Department Chairs to enhance the mission of the CancerCenter.7. Allocate Cancer Center space, approve membership applications, and represent the Cancer Center onthe College's Academic Council and on the Executive Committee of the Baylor Clinic.Dr. Osborne holds the Dudley and Tina Sharp Chair for Cancer Research and is also the Director of the BreastCenter. He received his M.D. degree from the University of Missouri School of Medicine in 1972, followed byinternal medicine training at Johns Hopkins, and a medical oncology fellowship at the National Cancer Institute.He then moved to the University of Texas Health Science Center at San Antonio in 1977 where he and his latecolleague, William McGuire, M.D., built an internationally recognized breast cancer program. Dr. Osborne roseto be Professor of Medicine and the Director of the Division of Oncology and Program Leader of the BreastCancer Program at the Cancer Center at that institution. In 1999, he and his group moved to Baylor College ofMedicine to create a Breast Center in Houston. Dr. Osborne is a Board Certified Medical Oncologist who hasbeen specializing in breast cancer for more than 25 years. He is also a well recognized translational scientist,and his laboratory has been continuously funded since 1978. He is recognized for his work on estrogenreceptor function, mechanisms of resistance to endocrine therapy, and crosstalk between ER and growthfactor receptor pathways. He has more than 300 publications in his career and has received many awards forhis research. Dr. Osborne has been the principal investigator of a Program Project Grant in breast cancer thathas been continuously funded since 1980. He is also the principal investigator on a breast cancer SPOREgrant that has been continuously funded since 1992. He has relinquished his role as principal investigator ofthe PPG to a colleague in order to be able to devote more time to directing the Cancer Center. He will stillhave a role in the research program of the PPG.Dr. Osborne has considerable administrative experience. He was chair of the Breast Committee for theSouthwest Oncology Group for many years and was one of the founding members of the Intergroup BreastCommittee, which oversees the major phase 3 breast cancer trials performed in this country. He was theDirector of the Division of Medical Oncology at the UT Health Science Center at San Antonio for 7 years priorto moving to Houston to become Director of the Breast Center. He has served on numerous local, national,and international committees, and for 15 years has been co-director of the San Antonio Breast CancerSymposium, the largest annual symposium devoted to breast cancer research, now attracting more than 7000attendees from over 80 countries. He previously served as Executive Officer for the Southwest OncologyGroup. He was a member of the American Society of Clinical Oncology Board of Directors from 1992-1995 andtheir Executive Committee from 1994-1997. Dr. Osborne has served on the External Advisory Boards ofseveral Cancer Centers and was a member of the NIH Reproductive Endocrinology Study Section.(50% effort, salary support requested)
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
| Ramdani, Ghania; Schall, Nadine; Kalyanaraman, Hema et al. (2018) cGMP-dependent protein kinase-2 regulates bone mass and prevents diabetic bone loss. J Endocrinol 238:203-219 |
| Nguyen, Vi; Marmor, Rebecca A; Ramamoorthy, Sonia L et al. (2018) The Use of Solicited Publishing by Academic Surgeons. Surgery 164:212-218 |
Showing the most recent 10 out of 862 publications
